2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-149119
    trans-2-Decenoylcoenzyme A 10018-95-8 98%
    trans-2-Decenoylcoenzyme A is a coenzyme A derivative.
    trans-2-Decenoylcoenzyme A
  • HY-149152
    PtdIns-(4,5)-P2 (1,2-dioctanoyl) 204858-53-7 98%
    PtdIns-(4,5)-P2 (1,2-dioctanoyl) is a synthetic derivative of phosphatidylinositol.
    PtdIns-(4,5)-P2 (1,2-dioctanoyl)
  • HY-149157
    L-Lysine orotate 28003-86-3 98%
    L-Lysine orotate is a salt of L-lysine and orotic acid that can potentiate the toxicity of an extract of the mushroom Amanita phalloides.
    L-Lysine orotate
  • HY-149193
    5-Taurinomethyluridine 497258-53-4 98%
    5-Taurinomethyluridine is a taurine-containing modified uridine and translation regulator that exists in Trp and Leu (UUR) tRNAs of mammalian mitochondria. 5-Taurinomethyluridine is located at the first position of the anticodon of these mitochondrial tRNAs. 5-Taurinomethyluridine is synthesized from taurine and one-carbon metabolites by GTPBP3/MTO1, and its deficiency directly causes abnormal mitochondrial translation and various human mitochondrial diseases.
    5-Taurinomethyluridine
  • HY-149218
    THR-β agonist 6 2791290-58-7 98%
    THR-β agonist 6 is an orally active, selective thyroid hormone receptor β (THR-β) agonist with EC50s of 0.03 μM and 0.22 μM for THR-β and THR-α, respectively. THR-β agonist 6 exhibits an xcellent liver-to-serum ratio of 93:1 in mice. THR-β agonist 6 has the potential for nonalcoholic steatohepatitis (NASH) research.
    THR-β agonist 6
  • HY-149254
    PTP1B/AKR1B1-IN-1 98%
    PTP1B/AKR1B1-IN-1 is a dual inhibitor of protein tyrosine phosphatase 1B (PTP1B) and aldose reductase (AKR1B1), with IC50s of 0.06 μM and 4.3 μM, respectively. PTP1B/AKR1B1-IN-1 also inhibits TC-PTP with an IC50 value of 9 μM. PTP1B/AKR1B1-IN-1 serves as an insulin-mimetic agent in murine myoblasts, and reduces AKR1B1-dependent sorbitol accumulation. PTP1B/AKR1B1-IN-1 inhibits development of type 2 diabetes mellitus (T2DM) to control blood glucose levels.
    PTP1B/AKR1B1-IN-1
  • HY-149255
    PTP1B/AKR1B1-IN-2 98%
    PTP1B/AKR1B1-IN-2 (Compound 7f) is a dual PTP1B/AKR1B1 inhibitor (IC50s: 3.2 and 2.1 μM, Kis: 4.0 and 0.9μM). PTP1B/AKR1B1-IN-2 is an insulin-mimetic agent. PTP1B/AKR1B1-IN-2 improves glucose uptake in murine C2C12 myoblasts. PTP1B/AKR1B1-IN-2 can be used for research of Type 2 diabetes mellitus (T2DM).
    PTP1B/AKR1B1-IN-2
  • HY-14930S
    Mirodenafil-d7 1329651-11-7 98%
    Mirodenafil-d7 (SK3530-d7) is the deuterium labeled Mirodenafil (HY-14930). Mirodenafil (SK3530) is an orally active, potent, reversible, and selective?phosphodiesterase?5 (PDE5)?inhibitor. Mirodenafil is a?glucocorticoid receptor?(GR)?modulator Mirodenafil activates the?Wnt/β-catenin?signaling pathway by downregulating Dkk1 expression. Mirodenafil can be used for the research of erectile dysfunction (ED), Alzheimer’s disease (AD) and systemic sclerosis (SSc).
    Mirodenafil-d7
  • HY-149310
    Dim16 2743448-32-8 98%
    Dim16 is a dual PCSK9 inhibitor and HMG-CoAR inhibitor, with an IC50 of 0.8 nM against human PCSK9 and an IC50 of 146.8 μM against HMG-CoAR. Dim16 disrupts the PCSK9-LDLR protein-protein interaction, inhibits the catalytic activity of HMG-CoAR, enhances cellular uptake of extracellular LDL, and suppresses PCSK9-induced platelet aggregation. Dim16 can be used in research related to hypercholesterolemia.
    Dim16
  • HY-149313
    α‑Amylase-IN-1 148404-10-8 98.33%
    α Amylase-IN-1 (Compound 11) is an α-Amylase inhibitor with an IC50 value of 0.5509 μM. α Amylase-IN-1 has antioxidant activity with an IC50 value of 53.49 μM for scavenging DPPH free radicals. IC50 can be used in the study of diabetes and oxidative stress-related diseases.
    α‑Amylase-IN-1
  • HY-149332
    α-Glucosidase-IN-26 98%
    α-Glucosidase-IN-26 (Compound 7i) is an α-glucosidase inhibitor (IC50=4.63 µM). α-Glucosidase-IN-26 can be used in the study of type 2 diabetes mellitus (T2DM).
    α-Glucosidase-IN-26
  • HY-149341
    α-Glucosidase-IN-28 2949513-10-2 98%
    α-Glucosidase-IN-28 (Compound 18) is a α-Glucosidase inhibitor (IC50: 0.62 μM, Ki: 3.93 μM). α-Glucosidase-IN-28 binds to α-glucosidase at the original binding site (OBS), and forms multiple hydrophobic interactions with nearby amino acids. α-Glucosidase-IN-28 can be used for research of diabetes and related diseases.
    α-Glucosidase-IN-28
  • HY-149342
    α-Glucosidase-IN-29 2949513-11-3 98%
    α-Glucosidase-IN-29 (compound 19) is a α-glucosidases inhibitor (IC50=1.21 μM, Ki=1.80 μM). α-Glucosidase-IN-29 ca be used for research of diabetes and related diseases.
    α-Glucosidase-IN-29
  • HY-149377
    MMP13-IN-4 514855-02-8 98%
    MMP13-IN-4 (compound 13) is a potent and selective inhibitor of MMP-13 (IC50=14.6 μM)，involved in osteoarthritis (OA).
    MMP13-IN-4
  • HY-149378
    MMP13-IN-5 98%
    MMP13-IN-5 (compound 13m) is a potent and selective inhibitor of MMP-2/MMP-13 (IC50=3.6 μM/14.6 μM)，involved in osteoarthritis (OA).
    MMP13-IN-5
  • HY-149405
    Squalene synthase-IN-1 98%
    Squalene synthase-IN-1 (compound 1) is a potent antihyperlipidemic agent acting through Squalene Synthase inhibition. Squalene synthase-IN-1 exhibits an outstanding antioxidant and anti-inflammatory activity. Squalene synthase-IN-1 displays a significant reduction not only of glucose but also of oxidative stress levels, while it did not cause any toxicity.
    Squalene synthase-IN-1
  • HY-149409
    α-Glucosidase-IN-31 98%
    α-Glucosidase-IN-31 (compound R1) is an orally active, potent α-Glucosidase inhibitor with an IC50 value of 10.1 μM. α-Glucosidase-IN-31 significantly reduces the blood glucose level and has antidiabetic activity.
    α-Glucosidase-IN-31
  • HY-149429
    PPARδ agonist 9 928023-21-6 98%
    PPARδ agonist 9 (compound 21) is a PPARδ agonist (EC50: 3.6 nM). PPARδ agonist 9 has in vivo efficacy, reducing serum levels of MCP-1 in mice and significantly inhibiting atherosclerosis progression in the LDLr-KO model (inhibition rate: 50-60%).
    PPARδ agonist 9
  • HY-149500
    CITFA 2379989-52-1 98%
    CITFA is a GPER agonist. CITFA can promote neurite growth of hippocampal neurons in rat embryo (E18).
    CITFA
  • HY-149532
    α-Glucosidase-IN-33 98%
    α-Glucosidase-IN-33 (compound 7c) is a potent α-glucosidase inhibitor (IC50: 2.39 μM) and can be used in the study of type 2 diabetes and hyperglycemia.
    α-Glucosidase-IN-33
Cat. No. Product Name / Synonyms Application Reactivity